WeVote
Log In

Bill

Bill

SF 4521

Hospital reimbursement for certain biological products to treat rare diseases provisions modifications

2025-2026 Regular Session Introduced by Liz Boldon and 1 co-sponsor

SF 4521 modifies hospital reimbursement rules for rare disease biological products, affecting treatment access, costs, and healthcare provider financial sustainability in Minnesota.

Referred to Health and Human Services
#healthandhealthdepartment #hospitalsandhealthcarefacilities
0
WeVote Research Nonpartisan
Bill Summary · SF 4521

Legislative bill overview

SF 4521 modifies Minnesota's hospital reimbursement provisions for biological products used to treat rare diseases. The bill adjusts how hospitals are compensated when administering these specialized treatments, potentially expanding coverage or changing reimbursement methodologies for high-cost biologics.

Why is this important

Rare disease treatments are often extremely expensive, and reimbursement disputes can prevent patients from accessing life-saving therapies. Hospital financial viability depends on adequate compensation, while payers seek to control costs. This bill balances those competing interests by clarifying reimbursement rules in Minnesota's healthcare system.

Potential points of contention

  • Cost implications: Changes could increase insurance premiums and state healthcare spending if reimbursement rates are raised, or reduce hospital access to rare disease treatments if rates are lowered
  • Market access: Unclear whether modifications encourage or restrict availability of certain biological products, potentially affecting patient choice and treatment options
  • Implementation burden: Hospitals and payers may face administrative complexity in implementing new reimbursement formulas, particularly for tracking biological product usage and costs

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.